Induction of centrosome amplification and chromosome instability in human bladder cancer cells by p53 mutation and cyclin E overexpression

Cancer Research

Volumn 64, Issue 14, 2004, Pages 4800-4809

  Kawamura, Kenji ^a,b   Izumi, Hideki ^a   Ma, Zhiyong ^a   Ikeda, Ryosuke ^b   Moriyama, Manabu ^b   Tanaka, Tatsuro ^b   Nojima, Takayuki ^b   Levin, Linda S ^a   Fujikawa Yamamoto, Kohzaburo ^b   Suzuki, Koji ^b   Fukasawa, Kenji ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN E; PROTEIN P53;

ANIMAL CELL; ARTICLE; BLADDER CANCER; CANCER CELL; CENTROSOME; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DUPLICATION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CENTROSOME; CHROMOSOMAL INSTABILITY; CYCLIN E; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 3142760098     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3908     Document Type: Article

References (50)

1. Doxsey S. Duplicating dangerously: linking centrosome duplication and aneuploidy. Mol Cell 2002;10:439-40.
2. D'Assoro AB, Lingle WL, Salisbury JL. Centrosome amplification and the development of cancer. Oncogene 2002;21:6146-53.
3. Doxsey S. Re-evaluating centrosome function. Nat Rev Mol Cell Biol 2001;2:688-98.
4. Fukasawa K. Centrosome: introduction. Oncogene 2002;21:6140-5.
5. Mazia D. The chromosome cycle and the centrosome cycle in the mitotic cycle. Int Rev Cytol 1987;100:49-92.
6. Nigg E. Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2002;2:815-25.
7. Tarapore P, Fukasawa K. Loss of p53 and centrosome hyperamplification. Oncogene 2002;21:6234-40.
8. Deng CX. Roles of BRCA1 in centrosome duplication. Oncogene 2002;21:6222-7.
9. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996;271:1744-7.
10. Wang XJ, Greenhalgh DA, Jiang A, et al. Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53 172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function. Mol Carcinog 1998;23:185-92.
11. Murphy KL, Dennis AP, Rosen JM. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J 2000;14:2291-302.
12. Fukasawa K, Wiener F, Vande Woude GF, Mai S. Genomic instability and apoptosis are frequent in p53 deficient mice. Oncogene 1997;15:1295-302.
13. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 2003;63:4862-71.
14. Duensing S, Lee LY, Duensing A, et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci USA 2000;97:10002-7.
15. Bunz F, Fauth C, Speicher MR, et al. Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res 2002;62:1129-33.
16. Weber RG, Bridger JM, Benner A, et al. Centrosome amplification as a possible mechanism for numerical chromosome aberrations in cerebral primitive neuroectodermal tumors with TP53 mutations. Cytogenet Cell Genet 1998;83:266-9.
17. Kawamura K, Moriyama M, Shiba N, et al. Centrosome hyperamplification and chromosome instability in bladder cancer. Eur Urol 2003;43:505-15.
18. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997;13:261-91.
19. Hinchcliffe EH, Sluder G. Two for two: Cdk2 and its role in centrosome doubling. Oncogene 2002;21:6154-60.
20. Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2-cyclin E in centrosome duplication. Cell 2000;103:127-40.
21. Fisk HA, Winey M. The mouse Mps1p-like kinase regulates centrosome duplication. Cell 2001;106:95-104.
22. Chen Z, Indjeian VB, McManus M, Wang L, Dynlacht BD. CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev Cell 2002;3:339-50.
23. Ekholm SV, Zickert P, Reed SI, Zetterberg A. Accumulation of cyclin E is not a prerequisite for passage through the restriction point. Mol Cell Biol 2001;21:3256-65.
24. Botz J, Zerfass-Thome K, Spitkovsky D, et al. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol 1996;16:3401-9.
25. Ohtani K, Degregori J, Nevins JR. Regulation of the cyclin E gene by the E2F1 transcription factor. Proc Natl Acad Sci USA 1995;92:12146-50.
26. Mussman JG, Horn HF, Carroll PE, Okuda M, Donehower LA, Fukasawa K. Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. Oncogene 2000;19:1635-46.
27. Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 1997;3:171-91.
28. McGarvey TW, Tait E, Tomaszewski JE, Malkowicz SB. Expression of transforming growth factor-ā receptors and related cell-cycle components in transitional-cell carcinoma of the bladder. Mol Urol 1999;3:371-80.
29. Makiyama K, Masuda M, Takano Y, et al. Cyclin E overexpression in transitional cell carcinoma of the bladder. Cancer Lett 2000;151:193-8.
30. Schraml P, Bucher C, Bissig H, et al. Cyclin E overexpression and amplification in human tumours. J Pathol 2003;200:375-82.
31. Sidransky D, Escenbach AV, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-9.
32. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 in transitional cell carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
33. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
34. Cooper MJ, Haluschak JJ, Johnson D. p53 mutations in bladder carcinoma cell lines. Oncol Res 1994;6:569-79.
35. Rigby CC, Franks LM. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosome pattern and ultrastructure. Br J Cancer 1970;24:746-54.
36. Rasheed S, Gardner MB, Rongley RW, Nelson-Rees WA, Arnstein P. Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst 1977;58:881-90.
37. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
38. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300.
39. Heim S, Mandahl N, Mitelman F. Genetic convergence and divergence in tumor progression. Cancer Res 1988;48:5911-6.
40. Chiba S, Okuda M, Mussman JG, Fukasawa K. Genomic convergence and suppression of centrosome hyperamplification in primary p53-/- cells in prolonged culture. Exp Cell Res 2000;258:310-21.
41. Bernardini S, Adessi GL, Billerey C, Chezy E, Carbillet JP, Bittard H. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol 1999;162:1496-501.
42. Gao JP, Uchida T, Wang C, et al. Relationship between p53 gene mutation and protein expression: clinical significance in transitional cell carcinoma of the bladder. Int J Oncol 2000;16:469-75.
43. Richter J, Wagner U, Kononen J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000;157:787-94.
44. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis and G1/S regulatory genes. Mol Cell Biol 1995;15:4215-24.
45. Meraldi P, Lukas J, Fry AM, Bartek J, Nigg EA. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A. Nat Cell Biol 1999;1:88-93.
46. Yasmeen A, Berdel WE, Serve H, Muller-Tidow C. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn 2003;3:617-33.
47. Balczon R, Bao L, Zimmer WE, Brown K, Zinkowski RP, Brinkley BR. Dissociation of centrosome replication events from cycles of DNA synthesis and mitotic division in hydroxyurea-arrested Chinese hamster ovary cells. J Cell Biol 1995;130:105-15.
48. Waf1/Cip1 pathway. Oncogene 2001;20:3173-84.
49. Lee H, Larner JM, Hamlin JL. Cloning and characterization of Chinese hamster p53 cDNA. Gene 1997;184:177-83.
50. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.